Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bifikafusp alfa - Philogen

Drug Profile

Bifikafusp alfa - Philogen

Alternative Names: Anti-EDB-IL2 antibody conjugate; Anti-EDB-interleukin-2 antibody conjugate; Darleukin; Immunocytokine therapy; L19 interleukin-2 fusion-protein; L19-IL-2; L19-IL2 fusion protein

Latest Information Update: 18 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Philogen
  • Developer Bayer Schering Pharma; Maastricht Radiation Oncology; Philogen
  • Class Antineoplastics; Cytokines; Immunotherapies; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Interleukin-2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Diffuse large B cell lymphoma
  • No development reported Malignant melanoma; Renal cell carcinoma; Solid tumours
  • Discontinued Atherosclerosis; Head and neck cancer; Pancreatic cancer

Most Recent Events

  • 10 Oct 2023 Philogen terminates a phase-I/II trial in Diffuse large B cell lymphoma (Second-line therapy or greater, Combination therapy) in Germany (IV) (NCT02957019)
  • 01 Jun 2023 Philogen enters into a clinical trial collaboration and supply agreement with MSD for L19IL2
  • 04 Apr 2019 Phase-II clinical trials in Non-small cell lung cancer (Metastatic disease) in United Kingdom (IV) (NCT03705403)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top